Mark Worthington - Mar 3, 2025 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
General Counsel and CCO
Signature
/s/ Mark Worthington
Stock symbol
ATHA
Transactions as of
Mar 3, 2025
Transactions value $
$0
Form type
4
Date filed
3/4/2025, 04:28 PM
Previous filing
Jan 3, 2025
Next filing
Jul 2, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Award $0 +85.9K $0.00 85.9K Mar 3, 2025 Common Stock 85.9K $0.38 Direct F1
transaction ATHA Restricted Stock Units Award $0 +57.3K $0.00 57.3K Mar 3, 2025 Common Stock 57.3K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock.
F3 100% of the RSUs shall vest on the one (1) year anniversary of the grant date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the vesting date.